

**Certificate of Analysis Finished Product**

<b>Title</b>	:		
<b>Product Name</b>	AZIDIME Injection	<b>A.R. No.</b>	BD/FP/24/554
<b>Generic Name</b>	Ceftazidime for Injection IP 1gm	<b>Sampled qty.</b>	45 Vials
<b>Batch No.</b>	B24456B	<b>Sampled by</b>	Rakesh
<b>Batch Size</b>	4600 Vials	<b>Sampled on</b>	04/01/2025
<b>Mfg. Date</b>	12/2024	<b>Date of Testing</b>	04/01/2025
<b>Exp. Date</b>	11/2026	<b>Date of Release</b>	20/01/2025

S. No.	Tests	Specifications	Observations
1.	Description	A white dry powder filled in clear glass vial.	A white dry powder filled in clear glass vial.
2.	Identification (By HPLC)	In, assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the working standard solution.	Complies
3.	Uniformity of Weight	Average weight $\pm 10\%$	-1.73% & +1.44%
4.	Average weight	Informative.	1296.1 mg
5.	pH	5.0 to 7.5	6.93
6.	Loss On Drying	NMT- 13.5%	10.18%
7.	Particulate Matter (a.) Sub-Visible particle count (1.) Particles $\geq 10\mu\text{m}$ (2.) Particles $\geq 25\mu\text{m}$  (b.) Visual	NMT-6000/vial NMT-600/vial  The solution should be essentially free from extraneous, mobile undissolved particles, other than gas bubbles, unintentionally.	224/vial 2/vial  Complies
8.	Pyridine	NMT- 0.4%	Complies
9.	Sodium Carbonate (By AAS)	Weight accurately a quantity containing about 50mg of anhydrous Ceftazidime and dissolve in sufficient water to produce 100.00 ml. Dilute the resulting solution appropriately with water.	Complies
10.	Sterility	No microbial growth should be observed.	Complies
11.	Bacterial Endotoxins	NMT- 0.10 EU/mg of Ceftazidime.	Less than- 0.10 EU/mg of Ceftazidime.
12.	Assay Each vial Contains :		

<b>Analysis by</b> NAME: SUFIYAN ANSARI	<b>Checked by</b> NAME: SANDHYA	<b>Approved by</b> NAME: P. N. TRIPATHI
--	------------------------------------	--



**Title : Certificate of Analysis Finished Product**

Product Name	AZIDIME Injection	A.R. No.	BD/FP/24/554
Generic Name	Ceftazidime for Injection IP 1gm	Sampled qty.	45 Vials
Batch No.	B24456B	Sampled by	Rakesh
Batch Size	4600 Vials	Sampled on	04/01/2025
Mfg. Date	12/2024	Date of Testing	04/01/2025
Exp. Date	11/2026	Date of Release	20/01/2025

Ingredients	Labeled Claim	Found	% of labeled amount	Limits % of labeled amount
Ceftazidime (Sterile) IP Eq. to anhydrous Ceftazidime (A sterile mixture of Ceftazidime & Sodium Carbonate)	1000 mg	1030.05 mg	103.01%	90.0 to 105.0%

**Remarks:** In the opinion of the undersigned the sample referred to above is/ is not of the standard quality as The Drug & Cosmetic Act 1940 and the rules made there under. Complies/ not complies as per IP/BP/USP/THS.



Analysis by NAME: SUFIYAN ANSARI	Checked by NAME: SANDHYA	Approved by NAME: P. N. TRIPATHI
-------------------------------------	-----------------------------	-------------------------------------

1. Appearance	Information	
2. pH	5.0 to 7.5	
3. Particles	NMT-6000/ml	20 vial
(1) Particles >10µm	NMT-6000/ml	2 vial
(2) Particles >5µm	NMT-6000/ml	2 vial
(3) Visual	The solution should be essentially free from extraneous visible undissolved particles, other than gas bubbles, unintentionally.	Complies
4. Particles	NMT-0.5%	
5. Sodium Carbonate (By Pass)	Weight accurately a quantity containing about 50mg of anhydrous Ceftazidime and dissolve in sufficient water to produce 100 ml. Dilute the resulting solution approximately with 20 ml water.	
6. Sterility	Tested by membrane filtration	Complies
7. Bacterial Endotoxins	Tested by Limulus Amebocyte Enzyme Test (LAL)	Complies
8. Assay	Each vial contains	